Magnesium sulphate versus lytic cocktail for eclampsia.

Area of Science:

• Obstetrics and Gynecology
• Clinical Pharmacology
• Critical Care Medicine

Background:

• Eclampsia is a severe pregnancy complication characterized by seizures, often managed with various anticonvulsants.
• Pre-eclampsia precedes eclampsia, posing significant risks to both mother and fetus.

Purpose of the Study:

• To compare the efficacy and safety of magnesium sulfate versus lytic cocktail in treating women diagnosed with eclampsia.
• To determine the optimal anticonvulsant therapy for managing eclamptic seizures.

Main Methods:

• A systematic review of randomized controlled trials was conducted.
• Searched the Cochrane Pregnancy and Childbirth Group register and the Cochrane Controlled Trials Register.
• Included two trials with 199 women comparing magnesium sulfate and lytic cocktail.

Main Results:

• Magnesium sulfate demonstrated superior efficacy in preventing further eclamptic seizures (RR 0.09, 95% CI 0.03-0.24) with a number needed to treat of 3.
• Treatment with magnesium sulfate was associated with significantly less respiratory depression (RR 0.12, 95% CI 0.02-0.91).
• While magnesium sulfate showed a trend towards reducing maternal deaths, the difference was not statistically significant (RR 0.25, 95% CI 0.04-1.43).

Conclusions:

• Magnesium sulfate is the recommended anticonvulsant of choice for managing eclampsia.
• Lytic cocktail is not recommended and should be discontinued for eclampsia treatment.
• Further high-quality research may be needed to confirm the impact on maternal mortality.